bile duct cancer May 12, 2022 ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential Premium May 4, 2022 Juniper Biologics to Sell Helsinn's Truseltiq in Certain Asia-Pacific, Africa, Middle East Markets May 2, 2022 Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 18, 2022 Kinnate Doses First Patient in Phase I Trial of FGFR Inhibitor Apr 6, 2022 Innovent Biologics' Pemazyre Approved by China's NMPA for Bile Duct Cancer Jan 19, 2022 FDA Clears Kinnate Biopharma's IND for FGFR Inhibitor in Bile Duct, Urothelial Cancers Jan 4, 2022 Relay Therapeutics Advances Trials of PI3Kα, FGFR2 Inhibitors Dec 20, 2021 Helsinn Group Licenses Truseltiq to Xediton Pharmaceuticals for Sale in Canada Nov 17, 2021 WUSTL Program Aims to Improve Sequencing Rates, Clinical Trial Participation Among Black Cancer Patients Premium Oct 25, 2021 TCR2 Therapeutics, BMS to Study Gavo-Cel, Opdivo, Yervoy Combos in Mesothelin-Expressing Cancers Jul 22, 2021 NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer Jul 9, 2021 Chinese Regulators Accept Innovent's New Drug Application for Pemazyre May 28, 2021 FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx May 25, 2021 Innovent Biologics Begins Phase III Trial of First-Line Pemazyre for Bile Duct Cancer in China Mar 31, 2021 QED Therapeutics, Helsinn Group Ink $2B Agreement to Codevelop Infigratinib in Oncology Mar 30, 2021 European Commission Approves Incyte's Pemazyre for Rare Bile Duct Cancer Mar 23, 2021 Incyte's Pemazyre Approved in Japan for Biliary Tract Cancer With FGFR2 Fusions Mar 1, 2021 Agios Submits sNDA for Tibsovo in IDH1-Mutant Bile Duct Cancer Feb 4, 2021 InnoCare Begins ICP-192 Study in US in FGFR-Altered Cancers Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week: Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
